Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSTAT versus DYANAVEL XR 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSTAT versus DYANAVEL XR 5.
DEXTROSTAT vs DYANAVEL XR 5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextroamphetamine is a central nervous system stimulant that promotes release of dopamine and norepinephrine from presynaptic neurons, and inhibits their reuptake, thereby increasing synaptic concentrations of these neurotransmitters.
CNS stimulant; blocks reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their synaptic concentrations.
5-60 mg orally per day in divided doses, typically 5-10 mg 2-3 times daily, maximum 60 mg/day.
20 mg orally once daily in the morning; may increase by 10 mg weekly based on response; maximum 60 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 10-13 hours in adults, 6-8 hours in children. Extended duration allows once-daily dosing in some patients.
Terminal elimination half-life for d-amphetamine is 10-13 hours; for l-amphetamine, 13-16 hours. Clinical context: Twice-daily dosing may be required for sustained effect.
Primarily renal (approximately 90% as unchanged drug and metabolites); minor biliary/fecal elimination (<10%).
Renal: ~90% as unchanged amphetamine and metabolites. Fecal: minimal (<5%).
Category C
Category C
CNS Stimulant
CNS Stimulant